Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...

As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...